AA
The company develops small molecular chimeras and dimeric scaffolds using a proprietary linker platform to enhance the efficacy of lead compounds in drug development. This technology enables healthcare companies to optimize treatments for complex diseases in oncology, inflammation, and ophthalmology.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- The company develops small molecular chimeras and dimeric scaffolds using a proprietary linker platform to enhance the efficacy of lead compounds in drug development. This technology enables healthcare companies to optimize treatments for complex diseases in oncology, inflammation, and ophthalmology.